Skip to main content

Table 5 Recommended doses and dose ranges for levomepromazine in nausea and vomiting

From: Evidence for the use of Levomepromazine for symptom control in the palliative care setting: a systematic review

Author

Year

Study design

Mean dose (mg/24 h)

Dose range (mg/24 h)

Findings

Molassiotis [47]

2010

survey study

no data

no data

second or third line for refractory chemotherapy-related nausea and vomiting

Stephenson [48]

2006

non-comparative prospective study

no data

6.25–25

first line in indeterminate pathophysiological causes and second line for all other causes of nausea and vomiting

Eisenchlas [13]

2005

open-label prospective study

6.25

3.12- 25

second line

Amesbury [49]

2004

case report

no data

12.5 -25

first line indication: 5HT2 antagonist property of levomepromazine is used because large amounts of circulating 5-HT are present in carcinoid syndrome

Kennett [50]

2004

quasi experimental prospective study

no data

6.25-25

second line or for indeterminate pathophysiological causes

Higi [51]

1980

prospective study

no data

16-30

second line in chemotherapy induced nausea

Davis [23]

2010

SR

nox data

no data

based on [13, 49, 50]

Glare [52]

2004

SR

no data

no data

based on one study [55] (not available)